XLV240920C173000
- 0.02
- 0.000.00%
The Health Care Select Sector SPDR® Fund Newsroom
Exchange-Traded Funds, Equity Futures Higher Pre-Bell Tuesday Ahead of US FOMC Policy Meeting
TransDigm, BJ's Wholesale, AbbVie And More On CNBC's 'Final Trades'
Senseonics Eversense 365 Glucose Monitor Cleared in the U.S.
Sector-wise Weekly ETF Flows - Money Pours Out of Financials and Into Consumer Staples
BeyondSpring Plinabulin, Merck Keytruda Combo Shows Promise in NSCLC
What the Options Market Tells Us About UnitedHealth Group
A Closer Look at 8 Analyst Recommendations For Merck & Co
CG Oncology Surges 7%; Seen Benefitting From J&J Bladder Cancer Asset Data
Cantor Fitzgerald Reiterates Overweight on Merck & Co, Maintains $155 Price Target
Merck & Co Analyst Ratings
Eli Lilly Analyst Ratings
Moderna Was Most Shorted S&P 500 Healthcare Stock in August for Second Consecutive Month
NuCana Resistant Melanoma Treatment Data Shows Providing Some Relief After Disappointing Colorectal Cancer Data, Stock Surges
Johnson & Johnson Analyst Ratings
Immutep's Efti In Combination With MSD's KEYTRUDA Leads To Efficacy With Favourable Safety In First Line Head And Neck Cancer
Thermo Fisher Scientific Analyst Ratings
Reported Saturday, Johnson & Johnson Shares New Data on RYBREVANT in Metastatic Colorectal Cancer at ESMO Congress
Reported Sunday, Johnson & Johnson Reveals New Data on TAR-200 for Bladder Cancer Treatment
Reported Saturday, Merck's KEYTRUDA Plus Trastuzumab and Chemotherapy Extends Survival In Advanced Gastric Cancer Or GEJ Adenocarcinoma
Do Queasy Side Effects Mean the End of Weight-loss Drug Stock Hype?